New Developments in Chemical Countermeasures: CounterACT 2018
化学对抗新进展:CounterACT 2018
基本信息
- 批准号:9490163
- 负责人:
- 金额:$ 15万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-09-30 至 2021-08-31
- 项目状态:已结题
- 来源:
- 关键词:AccidentsAcetylcysteineAcuteAcute Lung InjuryAdvanced DevelopmentAlkylating AgentsAnimalsAntidotesApoptosisBackBindingBiochemicalBiological MarkersBreathingBronchiolitisCardiopulmonaryCessation of lifeChemicalsChronicChronic lung diseaseCoagulation ProcessCollaborationsCommunitiesConsciousCritical IllnessCyanidesDNA CrosslinkingDataDevelopmentDisastersDisease modelEnteralEpithelialEventExposure toFDA approvedFailureFamily suidaeFibrosisFosteringGasesGastric LavageGastric mucosaGoalsHeadHumanIndustryInjuryInternationalIntoxicationIntramuscularIntravenousLungMediatingMitochondriaModelingMusMustard GasOralOryctolagus cuniculusPatientsPharmaceutical PreparationsPhasePhysiciansPhysiologicalPirfenidonePlasminogen ActivatorPoisonPoisoningPreparationProcessPulmonary FibrosisRattusRecoveryRespiratory FailureRouteScientistSiteStomachSulfhydryl CompoundsTRP channelTestingTherapeutic AgentsToxic effectUnited States National Institutes of HealthVitamin B 12absorptionanalogbasecobinamideeffective therapyimprovedinhibitor/antagonistinjured airwaymass casualtymembermethyl isocyanatemodel developmentnanonanoformulationnanoparticlephotonicspre-clinicalpreventprogramspulmonary functionreceptorsafety studysodium thiosulfatesuccess
项目摘要
“Development of antidotes for toxic gases”
The goal of this Program is to create a systematic process for developing antidotes against toxic gaseous
chemicals by capitalizing on the proven track record of a team of physician-scientists backed by accomplished
basic scientists. We will examine two acute pulmonary and cardiopulmonary toxidromes caused by the
gaseous chemicals sharing common injury mechanisms: 1) alkylating agents, sulfur mustard (SM) and methyl
isocyanate (MIC), that cause DNA crosslinking/damage, apoptosis, airway epithelial and endothelial injury,
acute lung injury, and fibrosis, and 2) rapidly absorbed gases, methylmercaptan (CH3SH) and cyanide (HCN),
that cause systemic mitochondrial failure. These toxic chemicals were chosen based on: 1) capacity to cause
critical illness and death, 2) perceived threat(s), 3) recent and/or important past exposures, and 4) priorities of
the NIH/CounterACT, BARDA, DoD, and international community. Therapies being advanced in Projects 1, 3,
and 4 are intended as rescue countermeasures for mass casualty scenarios. Two of these (Projects 1 and 3)
are intended to be for acute inhalation accidents or disasters. In Project 1, for MIC, three classes of therapies
directed at receptor-mediated (TRP channel antagonist(s)), coagulation-related (plasminogen activator(s)), and
biochemical (thiol compounds) events will be investigated in a new preclinical acute inhalation model.
Therapies would be for immediate/delayed treatment, with intramuscular, airway, and enteral and/or
intravenous delivery for TRP channel antagonists, plasminogen activators, and thiol compounds, respectively.
In Project 2, the anti-fibrotic drugs pirfenidone and nintedanib will be evaluated via oral/airway delivery in a
fibrotic chronic lung disease model in rats following sublethal SM exposure." In Project 3, the vitamin B12
analog cobinamide and sodium thiosulfate, both of which react directly with methyl mercaptan, will be tested as
countermeasures against this acutely toxic gas in mice, rabbits, and pig models. In Project 4, a nanoparticle-
associated cobinamide (Cbn) will be evaluated as acute rescue countermeasure for oral NaCN intoxication in
rabbit and pig models. Because oral NaCN is absorbed as a gas (HCN) at the gastric mucosa, and since
victims often will not be conscious, gastric lavage delivery will be used. The Specific Aims are: 1) Determine
potential of TRP channel antagonists, plasminogen activators, and thiols to decrease airway injury and lethality
after MIC inhalation; 2) Define the efficacy of pirfenidone and other anti-fibrotic drugs against airway and
parenchymal lung fibrosis after SM inhalation; 3) Establish efficacy of Cbn and thiosulfate for rescuing animals
from lethal methylmercaptan exposures and 4) test the potential efficacy of nonabsorbable nano preparations
of Cbn versus other Cbn preparations and routes in an oral NaCN poisoning and lethality model. Successful
therapies from each project will be ready for advanced development and attain pre-IND status at or before the
end of the cycle.
“开发有毒气体解毒剂”
该计划的目标是建立一个系统的过程,开发解毒剂,以对抗有毒气体
化学品,利用一个团队的医生,科学家支持的已证实的记录,
基础科学家我们将检查两种由细菌引起的急性肺和心肺中毒。
气体化学品共享共同的伤害机制:1)烷化剂,硫芥(SM)和甲基
异氰酸酯(MIC),其引起DNA交联/损伤、细胞凋亡、气道上皮和内皮损伤,
急性肺损伤和纤维化,和2)快速吸收的气体,甲基硫(CH 3 SH)和氰化物(HCN),
导致系统性线粒体衰竭这些有毒化学物质的选择是基于:1)造成
严重疾病和死亡,2)感知的威胁,3)最近和/或重要的过去暴露,以及4)
NIH/CounterACT、巴尔达、国防部和国际社会。项目1、3、4、5、6、7、8、9、10、11、12、14、15、16、17、18、19、
和4旨在作为大规模伤亡情况下的救援对策。其中两个(项目1和3)
用于急性吸入事故或灾难。在项目1中,对于MIC,有三类治疗
针对受体介导的(TRP通道拮抗剂)、凝血相关的(纤溶酶原激活剂)和
将在新的临床前急性吸入模型中研究生物化学(硫醇化合物)事件。
治疗将是立即/延迟治疗,肌内、气道和肠内和/或
分别用于TRP通道拮抗剂、纤溶酶原激活剂和硫醇化合物的静脉内递送。
在项目2中,抗纤维化药物吡非尼酮和尼达尼布将通过口服/气道给药进行评价,
亚致死剂量SM暴露后大鼠纤维化慢性肺病模型。“在项目3中,维生素B12
类似物可宾酰胺和硫代硫酸钠,两者都直接与甲基苯丙胺反应,将作为
在小鼠、兔子和猪模型中研究了针对这种急性毒性气体的对策。在项目4中,一种纳米颗粒-
相关的可宾酰胺(CBN)将被评估为口服NaCN中毒的急性抢救对策,
兔子和猪的模型。因为口服NaCN在胃粘膜处作为气体(HCN)被吸收,
受害者往往会意识不清,便采用洗胃分娩。具体目标是:1)确定
TRP通道拮抗剂、纤溶酶原激活剂和硫醇降低气道损伤和致死率的潜力
MIC吸入后; 2)确定吡非尼酮和其他抗纤维化药物对气道的疗效,
SM吸入后肺实质纤维化; 3)确定CBN和硫代硫酸盐用于拯救动物的功效
和4)测试不可吸收的纳米制剂的潜在功效
在口服NaCN中毒和致死模型中,比较CBN与其他CBN制剂和途径。成功
每个项目的治疗将准备好进行高级开发,并在或之前达到IND前状态。
循环的结束。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Carl W White其他文献
CXCL17 induces activation of human mast cells via MRGPRX2
CXCL17 通过 MRGPRX2 诱导人类肥大细胞激活
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:0
- 作者:
Jie Ding;Christina Hillig;Carl W White;Nithya A Fernandopulle;Holly Anderton;Johannes S Kern;Michael P. Menden;Graham A Mackay - 通讯作者:
Graham A Mackay
3 ROS : reactive oxygen species RT-qPCR : reverse transcription quantitative PCR SM : sulfur mustard SpO 2 : peripheral oxygen saturation tPA : tissue plasminogen activator
3 ROS : 活性氧 RT-qPCR : 逆转录定量 PCR SM : 硫芥 SpO 2 : 外周血氧饱和度 tPA : 组织纤溶酶原激活剂
- DOI:
- 发表时间:
2023 - 期刊:
- 影响因子:0
- 作者:
Heidi J. Nick;Carly A Johnson;Amber R. Stewart;Sarah Christeson;A. Leslie;Bloomquist;Amanda S. Appel;A. Donkor;L. Veress;B. Logue;E. Preston;Bratcher;Carl W White - 通讯作者:
Carl W White
Carl W White的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Carl W White', 18)}}的其他基金
Hypoxic-Inducible Factors in Neonatal Pulmonary Hypertension
新生儿肺动脉高压的缺氧诱发因素
- 批准号:
8214146 - 财政年份:2011
- 资助金额:
$ 15万 - 项目类别:
Novel antioxidant therapeutics for sulfur mustard toxicity (U54)
针对硫芥毒性的新型抗氧化疗法 (U54)
- 批准号:
7294907 - 财政年份:2006
- 资助金额:
$ 15万 - 项目类别:
Novel therapeutics for vesicants and toxic inhaled chemicals (U54)
针对出疱剂和有毒吸入化学品的新型疗法 (U54)
- 批准号:
8737370 - 财政年份:2006
- 资助金额:
$ 15万 - 项目类别:
相似海外基金
抗酸化能を高めたN-acetylcysteineによる老視と白内障抑制機構の解明
阐明具有增强抗氧化能力的N-乙酰半胱氨酸抑制老花眼和白内障的机制
- 批准号:
23K15945 - 财政年份:2023
- 资助金额:
$ 15万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Targeting the neurobiology of restricted and repetitive behaviors in children with autism using N-acetylcysteine
使用 N-乙酰半胱氨酸针对自闭症儿童限制性和重复性行为的神经生物学
- 批准号:
10758985 - 财政年份:2023
- 资助金额:
$ 15万 - 项目类别:
Targeting the neurobiology of restricted and repetitive behaviors in children with autism using N-acetylcysteine
使用 N-乙酰半胱氨酸针对自闭症儿童限制性和重复性行为的神经生物学
- 批准号:
10619173 - 财政年份:2022
- 资助金额:
$ 15万 - 项目类别:
High dose acetaminophen with n-acetylcysteine rescue as a novel STAT3 inhibitor with anti-cancer stem cell properties
高剂量对乙酰氨基酚与 n-乙酰半胱氨酸救援作为具有抗癌干细胞特性的新型 STAT3 抑制剂
- 批准号:
10517287 - 财政年份:2021
- 资助金额:
$ 15万 - 项目类别:
A randomised controlled trial of N-acetylcysteine for the treatment of alcohol use disorder
N-乙酰半胱氨酸治疗酒精使用障碍的随机对照试验
- 批准号:
nhmrc : 2001375 - 财政年份:2021
- 资助金额:
$ 15万 - 项目类别:
Clinical Trials and Cohort Studies Grants
High dose acetaminophen with n-acetylcysteine rescue as a novel STAT3 inhibitor with anti-cancer stem cell properties
高剂量对乙酰氨基酚与 n-乙酰半胱氨酸救援作为具有抗癌干细胞特性的新型 STAT3 抑制剂
- 批准号:
10368472 - 财政年份:2021
- 资助金额:
$ 15万 - 项目类别:
N-acetylcysteineの骨治癒促進効果の検討
N-乙酰半胱氨酸促进骨愈合作用的考察
- 批准号:
20H01118 - 财政年份:2020
- 资助金额:
$ 15万 - 项目类别:
Grant-in-Aid for Encouragement of Scientists
Targeting the neurobiology of restricted and repetitive behaviors in children with autism using N-acetylcysteine
使用 N-乙酰半胱氨酸针对自闭症儿童限制性和重复性行为的神经生物学
- 批准号:
10221760 - 财政年份:2020
- 资助金额:
$ 15万 - 项目类别: